ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BridgeBio Pharma is taking two steps to raise cash. The biotech firm has licensed BBP-398, a SHP2 inhibitor in development to treat various cancers, to Bristol Myers Squibb for $90 million. And it has sold a priority review voucher, which is intended to encourage development of treatments for rare pediatric diseases, for $110 million. The US Food and Drug Administration gave BridgeBio the voucher last year when it approved Nulibry for molybdenum cofactor deficiency. BridgeBio has also been trying to cut costs after disappointing clinical trial results in December for a heart drug.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter